B-Cell Therapies in Relapsing Remitting and Primary Progressive Multiple Sclerosis: A Short Clinical Review

Antonio Giovanni Solimando* and Aldo Tomasichio

1Department of Biomedical Sciences and Human Oncology, Section of Internal Medicine "G. Baccelli", University of Bari Medical School, Bari, Italy
2Department of Basic Medical Science, Neuroscience and Sense Organs, Aldo Moro University, Bari, Italy

Abstract

The history of multiple sclerosis (MS) has been focused primarily on T cells. Nevertheless, T lymphocytes directed approaches miss to understand the complexity underlying the progressive disease. Novel evidences triggered both laboratory and clinical research in an attempt to pursue this possible mechanism of action and improve therapeutic options for patients with MS. For several years, there have been hints that B cells play an important role in MS pathophysiology, but only recently has interest increased in the role of B cell-directed therapies in MS.

With anti-B-cell treatment, part of the immune repertoire is targeted, but not completely in the lymph nodes or tissues. This does not seem to compromise the physiologic activity of our immune system.

Surprisingly, it seems possible to deplete B cells without compromising normal immune reactivity.

In this short review, these novel approaches are illustrated, and the new intriguing opportunities offered by B-cell directed therapy are summarized.

Keywords: B-Cell, Multiple sclerosis; Secondary progressive multiple sclerosis

Spectrum of Disease Progression in Multiple Sclerosis

As physicians and neuroscientists, we would like to prevent the development of increasing disability in multiple sclerosis (MS), which puts a great burden on the patient and caregivers [1]. In 1996, the US National Multiple Sclerosis Society (NMSS) Advisory Committee on Clinical Trials in Multiple Sclerosis defined the clinical subtypes of multiple sclerosis (MS) [1]. The Committee provided standardized definitions for four MS clinical courses: relapsing-remitting (RR), secondary progressive (SP), primary progressive (PP), and progressive relapsing (PR) [1]. Either relapsing or progressive disease can be characterized by severity of signs and symptoms, frequency of relapses, rate of worsening, residual disability, and impairment [1]. Primary progressive multiple sclerosis (PPMS) accounts for 10%-15% of the entire MS population [2]. Two thirds of all patients with MS present relapsing remitting multiple sclerosis (RRMS) [3] characterized by clinically evident bouts of disease activity. Disability also accrues as disease progresses. As showed in Figure 1, the relation between inflammation and neuroaxonal loss during the progression of MS is particular: during the early phase of MS inflammation grow. In the same period, neuroaxonal loss is at low level. When the disease turn in RRMS, inflammation decrease while neuroaxonal loss increases its level. In PPMS phase, the grade of inflammation becomes low while the neuroaxonal loss becomes preponderant. Cognitive, visual, and other clinical changes could provide clinical evidence for disease activity [1]. Once patients have transitioned from RRMS to secondary progressive multiple sclerosis (SPMS), the burden of disability becomes greater. Moreover, it is well known how disability relentlessly progresses from the start. Degree of recovery from an acute relapse was considered to be, in itself, not useful for determining or modifying MS phenotypes, but is instead a contributor to disease worsening over time [1]. We suggest using the term worsening in place of progressing especially for patients with relapsing forms of disease, reserving the term progression only for those in the progressive phase of MS, independent of relapse activity [1].

Inflammation and Neurodegeneration in Early and Late MS

Currently, inflammation and neurodegenerative component are the main substrate thought to be involved in the pathogenesis of diseases; indeed [4], during the earlier stages of RRMS, the disease is fully driven by strong inflammatory responses orchestrated by autoreactive T or B cells. As the disease evolves and as the progressive features dominate, the neurodegenerative mechanisms govern the evolving deficits and disability. However, in many instances, a mix of these processes is probably occurring (Figure 2) [5,6]. Tissue changes can be induced by several different mechanisms, directly related to the inflammatory process via T-cell and B-cell mediated inflammation or dependent on microglial activation leading to mitochondrial injury and oxidative burst [7]. Secondary complications include energy deficiency [7]. New MS lesions begin with perivascular cuffing by inflammatory mononuclear cells, predominantly T cells and macrophages, which infiltrate the surrounding white matter [8]. At sites of inflammation, the blood-brain barrier (BBB) is disrupted, but unlike vasculitis, the vessel wall is preserved [9]. Involvement of the humoral immune system is also evident; small numbers of B lymphocytes also infiltrate the nervous system, and myelin-specific autoantibodies are present on degenerating myelin sheaths [10]. As lesions evolve, there is prominent astrocytic proliferation (gliosis) [11]. Surviving oligodendrocytes or those that differentiate from precursor cells can partially remyelinate the surviving naked axons, producing so-called shadow plaques [10]. In many lesions,
Figure 1: Spectrum of disease progression in MS [1].

Figure 2: Inflammation and neurodegeneration in early and late MS [4-6].
oligodendrocyte precursor cells are present in large numbers but fail to differentiate and remyelinate [8-11]. Over time, ectopic lymphocyte follicles appear in perivascular and perimeningeal regions, consisting of aggregates of T and B cells and resembling secondary lymphoid structures [12]. Although relative sparing of axons is typical of MS, partial or total axonal destruction can also occur, especially within highly inflammatory lesions [4-9]. Thus, MS is not solely a disease of myelin, and neuronal pathology is increasingly recognized as a major contributor to irreversible neurologic disability [1-3]. Inflammation and plaque formation are present in the cerebral cortex, and significant axon loss indicating death of neurons is widespread, especially in advanced cases [4]. Axonal damage occurs in every newly formed MS lesion, and cumulative axonal loss is considered to be the major cause of progressive and irreversible neurologic disability in MS [5]. As many as 70% of axons are lost from the lateral corticospinal (e.g., motor) tracts in patients with advanced paraparesis from MS, and longitudinal MRI studies suggest there is progressive axonal loss over time within established, inactive lesions [1,2]. Knowledge of the mechanisms responsible for axonal injury is incomplete and, despite the fact that axonal transactions are most conspicuous in acute inflammatory lesions, it is still unclear whether demyelination is a prerequisite for axonal injury in MS [9]. Demyelination can result in reduced trophic support for axons, redistribution of ion channels, and destabilization of action potential membrane potentials [10]. Axons can adapt initially to these injuries; with time, distal and retrograde degeneration often occurs [9,10]. Therefore, promotion of remyelination and preservation of oligodendrocytes early in the disease course remain important therapeutic goals in MS [12]. Some evidence suggests that axonal damage is mediated directly by resident and invading inflammatory cells and their toxic products, in particular by microglia, macrophages, and CD8 T lymphocytes [7]. Activated microglia are particularly likely to cause axonal injury through the release of NO and oxygen radicals and via glutamate, which is toxic to oligodendrocytes and neurons [7,8]. Interestingly, NMDA (glutamate) receptors are expressed on naked axon membranes that have undergone demyelination, perhaps providing a mechanism for glutamate-mediated calcium entry and cell death [8].

CNS Inflammation and B Cells Role in the Pathophysiology of MS

In RRMS, T and B cells in the periphery play a very important role. In the progressive forms of MS, there may be a very decisive role played by innate immune system cells [7]. In the brain, these would be microglial cells. The history of MS has been focused primarily on T cells for some very good reasons [4]. First, the experimental model of autoimmune encephalomyelitis (EAE), particularly in mice, involves cell-directed immunopathology in the brain that simulates the acute activity with associated demyelination occurring in the brains of MS patients [5]. Nonetheless, this model misses to explain the progressive disease. It is even a flawed model for MS in general. The one thing about the model is that we can adoptively transfer the disease from an affected mouse to an unaffected mouse by using pure populations of activated T cells. That has probably driven much of the therapy focused on controlling T-cell subsets in MS. Nevertheless, we have known for many decades that B cells might have some role in MS because one of the characteristic biomarkers of the disease is oligoclonal bands in the cerebrospinal fluid (CSF) [6]. This finding implicates B cells as making immunoglobulins within the central nervous system (CNS). While we have never been able to determine what those immunoglobulins are doing there or how they might be specifically driving the disease, they are such a characteristic phenomenon of both RRMS and PPMS that one wonders why B cells might be a novel appealing target in MS treatment. Indeed, leptomengeal inflammation from secluded compartments of B-cell aggregates might contribute to the pathogenesis that leads to continuous disease progression [7].

The traditional view is that B cells are the source of autoantibodies crucial to the demyelination process [8]. More recently, B cells have an emerging role as antigen-presenting cells that instruct T cells to begin the immunoinflammatory cascade [9]. B cells are also thought to be builders of the local immune system, for example, in the progressive stages of MS (Figure 3) [10,11].

Moreover, in RRMS and PPMS, B cells play a very important role in the central nervous system (CNS)-occurring immune responses, forming the so-called compartmentalized inflammation and follicle-like structures. Nonetheless, this role still needs to be further explored [4]. Since inflammation occurs behind a closed BBB and B cells play a crucial role, anti-inflammatory drugs that act in the periphery have difficulty passing either a closed or a repaired BBB; furthermore, intrathecal anti-inflammatory therapy might be able to circumvent this. This might be the reason why BBB damage does not appear anymore a good measure of ongoing inflammatory disease activity [4].

Anti-CD20 Therapy in MS: Mechanisms of Action and Clinical Experience

Recent years have brought an emerging interest in the arena of B cell-targeted therapies Anti-B-cell therapy -- depletion or silencing of B cells-could conceptually work via several distinct mechanisms [12]. The background of effectiveness of immune mediated approach is the interaction with antigen presentation by CD20-positive B cells and consequent immunosuppression of T cells. Nevertheless, also the depletion of CD20 positive T cells corroborate this effect [13,14], in combination with anti-inflammatory effect by diminishing of proinflammatory cytokines produced by B cells [15]. It is also been shown that reduction of antibody production (in blood) with long-term treatment is related to a slight decline of IgM concentration, together with a largely unaltered IgG subclass [13]. On the other hand, T cells and CXCL13 are reduced in CSF [16]. On this basis B-Cell Depletion with Rituximab in RRMS: phase 2 HERMES trial, was conducted on 104 patients, randomly assigned 2:1. 69 patients received 1000 mg of intravenous Rituximab, and 35 patients received placebo; this trial showed that Rituximab really silenced the disease, which was the basis for using anti-CD20 in RRMS (Figure 4) [12].

Emerging data on B cell-targeting therapies have focused on a new anti-CD20 monoclonal antibody, ocrelizumab [17]. There are differences between rituximab and ocrelizumab from a molecular standpoint, as shown in Figure 5.

In addition: the epitopes recognized on CD20 by Rituximab and ocrelizumab are distinct but overlapping. The stronger antibody-dependent cellular cytotoxicity with ocrelizumab might translate to increased therapeutic efficacy. The reduced complement dependent cytotoxicity explains the lower frequency of infusion-related reactions (IRRs) [18]. Ocrelizumab has a modified Fc portion that potentially reduces AE related to complement activation (compared with rituximab). Additionally, higher affinity for FcgRIIA, including low affinity it has been developed. Overall, improved potency and potentially improved efficacy/safety profile has emerged [18]. Ocrelizumab has been investigated in two Identical Phase 3 Studies Evaluating in RRMS [19]. Data were recently released from the OPERA studies, which investigated the use of ocrelizumab in RRMS. These were 2 identical studies with ocrelizumab vs subcutaneous high-dose Interferon (IFN) β, 3 times weekly. In 2 years, ocrelizumab showed 2 identical studies with ocrelizumab vs subcutaneous high-dose Interferon (IFN) β, 3 times weekly. In 2 years, ocrelizumab showed
Figure 3: B cells in the pathophysiology of MS [8-11].

Gd-Enhancing Lesions in Each Study Group From Baseline to Week 48

Figure 4: B-cell depletion with rituximab in rrms: phase 2 hermes trial, was conducted on 104 patients, randomly assigned 2:1; 69 patients received 1000 mg of intravenous rituximab, and 35 patients received placebo; this trial showed that rituximab really silenced the disease, which was the basis for using anti-cd20 in rrms [12].
and confirmed disability progression (CDP), but also with MRI and brain atrophy [19]. The primary endpoint was significant reduction in ARR compared with IFNβ-1a and the secondary endpoints concerned significant reduction in CDP in the prespecified pooled analysis of OPERA OPERA II, and OPERA II, with reduction in MRI Lesions [19]. There have been many recent publications confirming a high correlation between brain atrophy and the development of disability, underlying the complementary predictive value of atrophy and lesion volumes for predicting long-term disability in MS [18,19]. Nonetheless, the reduction in brain volume loss with ocrelizumab was closer to what is seen in normal healthy controls [19]. What was predictable from the Rituximab experience, even if still concerning is IRRs, which can be decreased by pretreatment with steroids and anti-inflammatory drugs.

There was a little bit higher proportion of common infections, but nothing opportunistic, and of malignancies [19]. In light of these data, B cells are no longer strictly a diagnostic measure (oligoclonal bands-OCBs) in the CSF. Trial data seems to force to rethink the role of the B cell in MS. It is clear that B cells play a significant and pathogenic role because B-cell depletion has a large effect on multiple measure (ARR, MRI) (Figure 6) [20].

Other B cell-targeting therapies have failed in MS, including atacicept. Atacicept is a fusion protein that acts as a receptor for important survivor B-cell survival factors including BAFF and APRIL. This trial showed that not only patients did not receive any benefit from atacicept, but also they actually did worse on it [21]. Immunologic data for the reason behind these results are not available, but there is a theory: there are different populations of B cells; one drives proinflammatory activity, and the other regulates and counteracts overactive inflammation. It is possible that atacicept broadly targeted the B-cell population, including “regulatory” B cells, and deprived them of their survival factors. As a result, the regulatory influence of these cells was no longer exerted, and pathogenic activities prevailed. In light of such evidence is mandatory to validate any B-cell directed approach [21].

The results with fingolimod were particularly surprising [22]. It was considered an attractive candidate because of data showing that it acts both on the peripheral immune system and in the CNS [23-25]. A subgroup analysis of the Olimpus study showed that patients under 51 years of age, with at least one gadolinium (Gd)-enhancing lesions at baseline, fared much better than other patients [26] did. However, the number of patients was small and along with disease progression, the pathogenesis seems to be due to aging.

The older patients do not profit as much from this therapy because they have this additive pathology. Instead, the younger patients with active lesions on MRI may profit.

The ORATORIO study enrolled more than 700 patients, who were randomly assigned to either placebo or ocrelizumab. The duration of

| Antibody       | Type                     | ADCC | CDC  |
|----------------|--------------------------|------|------|
| Rituximab      | Chimeric IgG1            | ++   | ++   |
| Ocrelizumab    | Fully humanized IgG1     | +++  | +/-  |

Figure 5: Ocrelizumab vs. Rituximab characteristics [17,18].
the study was 120 weeks to be able to determine the 24-week CDP [30].
The average age was higher than in RRMS trials, around 44 years. It is
in the range where OLYMPUS showed positive results. Around 25%
of patients were also positive for Gd-enhancing lesions. The reduction
in the risk for CDP is very encouraging. Because there is a connection
between brain atrophy and disability progression, it is reassuring to
see that ocrelizumab also had an effect on brain volume loss in PPMS
within 120 weeks. There were also increased IRRs in this trial, as well as
slightly increased common infections. There were also a slightly increased
number of malignancies. This is important because of the mismatch in
the occurrence between ocrelizumab and placebo. These are relatively
small numbers, but we have to be cautious. Additional data are needed to
see whether this signal will persist and stand out against the background
prevalence of malignancies in this patient or age group.

The Role of B cells in the Pathogenesis of PPMS seems to
be Similar to that in RRMS.

However, there could be some differences in the PPMS population.
It is still a hypothesis that anti-CD20 therapy has an impact on
compartmentalized inflammation associated with progression. It is
possible that the anti-CD20 antibodies could go through the blood-
brain barrier, target the B-cell follicles, and have a therapeutic effect in
the CNS [12-16]. The patient population in ORATORIO was relatively
young compared with other big trials conducted in PPMS, and a
significant proportion of patients also had inflammatory activity on
baseline MRI. A recently presented post hoc analysis of the ORATORIO
data suggests that there was no difference in time to onset of 12- or
24-week CDP in patients who had Gd-enhancing lesions at baseline,
compared with those who did not. Many open questions remain, but
these data provide momentum and hope for patients with PPMS who
have been left out from the advances in therapies developed over the
years for RRMS [31].

Treat ing the Spectrum of MS with B Cell-Targeted
Therapies

Potential future roles for B cell-targeted therapies in MS, B cell-
directed therapies are effective in both RRMS and PPMS. If they
are effective in clinically isolated syndrome and SPMS, there would
be a therapeutic approach that covers the entire “spectrum of MS”.
Physicians may adopt ocrelizumab for the management of SPMS,
which constitutes a far larger proportion of the progressive population
than PPMS. Ideally, B cell-directed therapies would be given at the
beginning of PPMS, as soon as it is diagnosed or at least within 1 year.
Based on the data, there is no reason to wait longer to start therapy.

Ofatumumab is a fully human antibody, which targets epitope
distinct from rituximab, with similar ADCC to rituximab but stronger
CDC, even with low CD20 density. Moreover, ofatumumab it is
characterized by a more potent and prolonged B-cell depletion. A
phase 2 studies it has been completed and phase 3 results are expected.
Anti-CD19 antibodies are currently being developed for clinical trials.
The most advanced compound is MEDI-551, an affinity-optimized and
afucosylated humanized IgG1 kappa, with effect on B-cell depletion
primarily dependent on ADCC [18,32,33]. There is a need to find reliable
markers of B-cell depletion, when Rituximab was being investigated; the
persistence of B-cell depletion was gauged by measuring CD19 cells in
the periphery. There was no reliable correlation. Therefore, the decision
to reintroduce Rituximab was not based on peripheral blood CD19-positive cells but on the patient’s clinical picture. Data in experimental models suggest that there is a disproportionate effect of B-cell depletion in the periphery vs tissues. It is currently not known how frequently or for how long a powerful B cell-depleting agent can be administered to patients with MS without potentially encountering risks [13,14]. Moreover, robust evidence regarding the long-term use of B-cell therapy in MS is scanty. Nevertheless, a long-term safety and efficacy study it has been designed. Data were retrieved from the Swedish MS registry and through medical chart review for all patients ever treated with rituximab. Within 753 MS patients treated with B-cell depletion therapy, fewer than 15 severe adverse events (grade 3 or more) were detected, including generalized arthralgia, palmpoplantar pustulosis, bilateral noninfectious pulmonary infiltrates, and infusion related reactions. Preliminary analysis indicate a 1-year drug survival >90%. Rituximab showed a high degree of drug survival and a good tolerability profile with few treatment interruptions due to inadequate treatment response [34]. Nonetheless, data will have to be carefully collected, most likely in the context of a registry, to reassure that the good emerging safety profile of ocrelizumab from the pivotal trial will hold up [35].

Disclosures

None of the authors has any competing interests.

References

1. Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, et al. (2014) Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 83: 278-286.
2. Miller DH, Leary SM (2007) Primary-progressive multiple sclerosis. Lancet neurol 6: 903-912.
3. Kalincik T, Buzzard K, Jokubaitis V, Trojano M, Duquette P, et al. (2014) Risk of relapse phenotype recurrence in multiple sclerosis. Mult scler 20: 1511-1522.
4. Lassmann H, van Horssen J, Mahad D (2012) Progressive multiple sclerosis: pathology and pathogenesis. Nat rev neurol 8: 647-656.
5. Lassmann H (2013) Pathology and disease mechanisms in different stages of multiple sclerosis. J neurol sci 333: 1-4.
6. Kutzelnigg A, Lassmann H (2014) Pathology of multiple sclerosis and related inflammatory demyelinating diseases. Handb clin neurol 122: 15-58.
7. Schmitt N (2015) Role of t follicular helper cells in multiple sclerosis. J nat sci 1: e139.
8. Crawford A, Macleod M, Schumacher T, Corlet L, Gray D (2006) Primary t cell expansion and differentiation in vivo requires antigen presentation by b cells. J immunol 176: 3498-3506.
9. Bar-Or A, Fazaw L, Fan B, Darlington PJ, Rieger A, et al. (2010) Abnormal b-cell cytokine responses a trigger of t-cell-mediated disease in ms? Ann neurol 66: 452-461.
10. Lisak RP, Benjamins JA, Nedelkoska L, Barger JL, Ragheb S, et al. (2012) Secretory products of multiple sclerosis b cells are cytotoxic to oligodendroglia in vitro. J neuroimmunol 248: 85-95.
11. Weber MS, Hemmer B, Cepok S (2011) The role of antibodies in multiple sclerosis. Biochem biophys acta 1812: 239-245.
12. Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, et al. (2008) B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N engl j med 358: 676-688.
13. Piccio L, Naismuth RT, Trinkaus K, Klein RS, Parks BJ, et al. (2010) Changes in b- and t-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis. Arch neuro 67: 707-714.
14. Palanichamy A, Jahn S, Nickles D, Derstine M, Abounasr A, et al. (2014) Rituximab efficiently depletes increased cd20-expressing t cells in multiple sclerosis patients. J immunol 193: 080-086.
15. Mössner E, Brünker P, Moser S, Püntener U, Schmidt C, et al. (2010) Increasing the efficacy of cd20 antibody therapy through the engineering of a new type ii anti-cd20 antibody with enhanced direct and immune effector cell-mediated b-cell cytotoxicity. Blood 115: 4393-4402.
16. Schröder C, Azizinaddeh AM, Wu G, Price JD, Atkinson JB, et al. (2003) Anti-cd20 treatment depletes b-cells in blood and lymphatic tissue of cynomolgus monkeys. Transpl immunol 12: 19-28.
17. Bröck W, Gold R, Lund BT, Oreja-Guevara C, Prat A, et al. (2013) Thespeic decisions in multiple sclerosis: moving beyond efficacy. Jama neurol 70: 1315-1324.
18. Klein C, Lammens A, Schäfer W, Georges G, Schwager M, et al. (2013) Epitope interactions of monoclonal antibodies targeting cd20 and their relationship to functional properties. Mabs 5: 22-33.
19. Hauser SL, Comi GC, Hartung HP, Selmsják T, Traboulsee A, et al. (2015) Efficacy and safety of ocrelizumab in relapsing multiple sclerosis - results of the interferon-beta-1a-controlled, double-blind, phase iii opera i and ii studies. Program and s of the congress of the european committee for treatment and research in multiple sclerosis (ectrims).
20. Stangel M, Fredriksson S, Meinel E, Petzold A, Stüve O, et al. (2013) The utility of cerebrospinal fluid analysis in patients with multiple sclerosis. Nat rev neurol 9: 267-276.
21. Kappos L, Hartung HP, Freedman MS, Alexey B, et al. (2014) Atacicept in multiple sclerosis (atams): a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet neurol 13: 353-363.
22. Leary SM, Miller DH, Stevenson VL, Bex PA, Chand DT, et al. (2003) Interferon beta-1a in primary progressive ms: an exploratory, randomized, controlled trial. Neurology 60: 44-51.
23. Montalban X, Sastre-Garriga J, Tintoré M, Brieval L, Aymerich FX, et al. (2009) A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis. Mult scler 15: 1195-1205.
24. Wolinsky JS, Narayana PA, O’Connor P, Coyle PK, Ford C, et al. (2007). Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann neurol 61: 14-24.
25. Lublin F, Miller DH, Freedman MS, Cree BA, Wolinsky JS, et al. (2016) Informs study investigators. Oral fingolimod in primary progressive multiple sclerosis (informs): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 387: 1075-1084.
26. Hawker K, O’Connor P, Freedman MS, Calabresi PA, Antel J, et al. (2009) Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann neurol 66: 460-471.
27. Sedel F, Bernard D, Mock DM, Tourbah A (2015) Targeting demyelination and virtual hypoxia with high-dose biotin as a treatment for progressive multiple sclerosis. Neuropharmacology S0028-3908 (15) 30073-3.
28. Tourbah A, Frenay CL, Edan G, Clanet M, Papex C, et al. (2015) Effect of md1003 (high doses of biotin) in progressive multiple sclerosis: results of a pivotal phase iii randomized double blind placebo controlled study. Neurology 84: PL2.002.
29. Tourbah A, Lebrun-Frenay C, Edan G, Clanet M, Papex C, et al. (2015) Md1003 (high doses of biotin) in progressive multiple sclerosis: subgroup analyses of the ms-spi trial. Program and s of the congress of the european committee for treatment and research in multiple sclerosis (ectrims).
30. Montalban X, Hemmer B, Rammohan K, Gavin G, De Seze J, et al. (2016) Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis - results of the placebo-controlled, double-blind, phase iii orototo study. Clinical Trials in Multiple Sclerosis I.
31. Wolinsky J, Arnold DL, Bar-oar a, et al. (2016) Efficacy of ocrelizumab in patients with pmps with and without 1 gadolinium- enhancing lesions at baseline in a phase iii, placebo-controlled trial.
32. Chen D, Blazek M, Ireland S, Ortega S, Kong X, et al. (2012) Single dose of glycoengineered anti-cd19 antibody (med551) disrupts experimental autoimmune encephalomyelitis by inhibiting pathogenic adaptive immune responses in the bone marrow and spinal cord while preserving peripheral regulatory mechanisms. J immunol 2014:43. 4823-4832.
33. Hammes O (2012) C19 as an attractive target for antibody-based therapy. Mabs 4: 571-577.
34. Alping P, Frissel T, Novakova L, Islam-Jakobsson P, Salzer J, et al. (2016) Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Ann neurol 79: 95-108.
35. Jarius S, Paul F, Franciotta D, Waters P, Zipp F, et al. (2008) Changes in anti-cd20 antibody with enhanced direct and immune effector cell-mediated b-cell cytotoxicity. Blood 115: 4393-4402.